{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:42:31Z","timestamp":1785404551236,"version":"3.56.0"},"reference-count":25,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mexico\u2019s National Council of Science and Technology","award":["1074186"],"award-info":[{"award-number":["1074186"]}]},{"award":["1074186"],"award-info":[{"award-number":["1074186"]}],"id":[{"id":"https:\/\/ror.org\/059ex5q34","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union\u2019s Horizon 2020 research and innovation program","doi-asserted-by":"publisher","award":["875171"],"award-info":[{"award-number":["875171"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Immune checkpoint inhibitors (ICIs) have broadened treatment options for non-small cell lung cancer (NSCLC), but many patients show limited response. Baseline biomarkers and indices, including C-reactive protein (CRP), albumin, Neutrophil-to-Lymphocyte Ratio (NLR), Glasgow Prognostic Score (GPS), Prognostic Nutrition Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI), may predict treatment outcomes. This study evaluated whether these biomarkers associate with three-month mortality and disease progression assessed by disease control rate (DCR) using RECIST. Methods: We conducted a retrospective cohort study of consecutive patients with NSCLC from the OncoLifeS biobank (2015\u20132020). Three-month mortality was defined by status alive or deceased at three months after treatment start. DCR was based on CT-assessments using RECIST. Univariate and multivariable logistic regression models with backward selection and bootstrapping were developed to test biomarker associations with three-month mortality and DCR. Sensitivity analysis was performed to compare results with the standard definition of objective response rate (ORR). Results: Among 505 patients, 421 were alive and 84 deceased; 297 were responders and 208 non-responders. In the final progression model, higher GPS was associated with increased odds of 3-month progression, whereas higher ALI (OR 0.99, 95% CI 0.97\u20131.00) and higher PNI (OR 0.93, 95% CI 0.87\u20130.99) were associated with decreased odds of 3-month progression. Higher ALI (OR 0.97, 95% CI 0.94\u20130.99), and higher PNI (OR 0.83, 95% CI 0.78\u20130.89) were associated with lower odds of 3-month mortality. The mortality-model showed an AUC of 0.82 and 0.73 for the disease progression model. Sensitivity analysis with the standard RECIST definition revealed similar results. Conclusions: Higher GPS was associated with increased risk of progression, whereas higher PNI and ALI were associated with lower risk of progression and mortality. These findings warrant external validation before clinical implementation.<\/jats:p>","DOI":"10.3390\/cancers18142185","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:40:09Z","timestamp":1783525209000},"page":"2185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5326-6309","authenticated-orcid":false,"given":"Mirte","family":"Dekker","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-7405","authenticated-orcid":false,"given":"Erick","family":"Suazo-Zepeda","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-2160","authenticated-orcid":false,"given":"T. Jeroen N.","family":"Hiltermann","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-4471","authenticated-orcid":false,"given":"Geertruida H.","family":"De Bock","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein A.","family":"Heuvelmans","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Institute for Diagnostic Accuracy, 9713 GH Groningen, The Netherlands"},{"name":"Department of Respiratory Medicine, Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359\u201386","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA\u2014J. Am. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.21037\/tlcr-24-264","article-title":"Trends in the prescription of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis","volume":"13","author":"Maas","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2169531","DOI":"10.1080\/21645515.2023.2169531","article-title":"Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis","volume":"19","author":"Lu","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/1759-7714.15401","article-title":"The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"15","author":"Horstman","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: Pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4149\/318_151001N512","article-title":"Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib","volume":"63","author":"Fiala","year":"2016","journal-title":"Neoplasma"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Riedl, J.M., Barth, D.A., Brueckl, W.M., Zeitler, G., Foris, V., Mollnar, S., Stotz, M., Rossmann, C.H., Terbuch, A., and Balic, M. (2020). C-reactive protein (Crp) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study. Cancers, 12.","DOI":"10.3390\/cancers12082319"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e003536","DOI":"10.1136\/jitc-2021-003536","article-title":"Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer","volume":"9","author":"Alessi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.esmoop.2021.100254","article-title":"Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer","volume":"6","author":"Mountzios","year":"2021","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.11.026","article-title":"Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors","volume":"152","author":"Takamori","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non\u2013Small Cell Lung Cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-019-2122-x","article-title":"The OncoLifeS data-biobank for oncology: A comprehensive repository of clinical data, biological samples, and the patient\u2019s perspective","volume":"17","author":"Sidorenkov","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Greten1, 2, 3 SIG. Inflammation and Cancer: Triggers, Mechanisms and Consequences","volume":"51","author":"Florian","year":"2019","journal-title":"Immunity"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0161-5890(01)00042-6","article-title":"Human C-reactive protein: Expression, structure, and function","volume":"38","author":"Volanakis","year":"2001","journal-title":"Mol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12935-019-1027-3","article-title":"Role of the complement system in the tumor microenvironment","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"Il-6 in inflammation, Immunity, And disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12672-024-01153-3","article-title":"Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: A systematic review of real-world data","volume":"15","author":"Macioch","year":"2024","journal-title":"Discov. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:52:23Z","timestamp":1783525943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":25,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142185"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142185","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}